IL-1-driven systemic inflammation in tumour progression and metastatic spread

Area of Science:

• Immunology
• Oncology
• Molecular Biology

Background:

• Chronic inflammation is a key driver of cancer initiation and metastasis.
• Tumors actively induce systemic inflammation, creating a bidirectional relationship.
• Interleukin-1 (IL-1) cytokines, particularly IL-1β, are central mediators linking tumor activity to immune dysregulation.

Purpose of the Study:

• To synthesize current knowledge on how tumors induce IL-1 production.
• To elucidate how IL-1-driven systemic inflammation remodels the tumor microenvironment.
• To explore the therapeutic potential of targeting IL-1 signaling in cancer.

Main Methods:

• Review of existing literature on IL-1 family cytokines in cancer.
• Analysis of mechanisms by which tumors induce IL-1.
• Examination of IL-1's role in myeloid cell reprogramming and systemic inflammation.

Main Results:

• Tumor-derived IL-1β reshapes bone marrow hematopoiesis, favoring myeloid cell expansion.
• Tumor-educated myeloid cells (monocytes, neutrophils) promote disease progression and metastasis.
• IL-1 signaling contributes to the suppression of anti-tumor immunity.

Conclusions:

• IL-1 signaling is a critical pathway connecting cancer and systemic inflammation.
• Myeloid cell reprogramming by IL-1 occurs hierarchically across different tissues.
• Targeting IL-1 represents a promising strategy to disrupt tumor-promoting inflammation and enhance anti-tumor immunity.